Equities Analysts Issue Forecasts for TRDA FY2024 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Stock analysts at William Blair raised their FY2024 EPS estimates for Entrada Therapeutics in a research report issued on Tuesday, November 5th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of $1.19 for the year, up from their previous estimate of $0.43. The consensus estimate for Entrada Therapeutics' current full-year earnings is $0.68 per share. William Blair also issued estimates for Entrada Therapeutics' Q4 2024 earnings at ($0.69) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.95) EPS.

A number of other equities research analysts have also recently weighed in on the company. Oppenheimer increased their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday. HC Wainwright raised their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday.

Entrada Therapeutics Trading Up 3.1 %

NASDAQ:TRDA traded up $0.57 on Thursday, hitting $19.23. The company's stock had a trading volume of 276,281 shares, compared to its average volume of 105,353. Entrada Therapeutics has a one year low of $10.75 and a one year high of $19.85. The stock has a fifty day moving average of $16.33 and a two-hundred day moving average of $15.61. The firm has a market capitalization of $715.36 million, a P/E ratio of 6.30 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. The company had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million.

Insider Transactions at Entrada Therapeutics

In other news, CFO Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock in a transaction on Monday, September 9th. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15. Following the completion of the sale, the chief financial officer now owns 76,486 shares of the company's stock, valued at approximately $1,144,995.42. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Entrada Therapeutics news, CFO Kory James Wentworth sold 3,195 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15. Following the transaction, the chief financial officer now owns 76,486 shares in the company, valued at $1,144,995.42. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Natarajan Sethuraman sold 2,642 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.09, for a total value of $39,867.78. Following the sale, the insider now owns 183,816 shares of the company's stock, valued at approximately $2,773,783.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,187 shares of company stock worth $155,947. Company insiders own 7.59% of the company's stock.

Hedge Funds Weigh In On Entrada Therapeutics

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Entrada Therapeutics by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company's stock valued at $15,288,000 after purchasing an additional 13,742 shares in the last quarter. American Century Companies Inc. raised its stake in Entrada Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 384,973 shares of the company's stock worth $5,486,000 after acquiring an additional 18,625 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Entrada Therapeutics by 13.4% during the second quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company's stock worth $1,787,000 after acquiring an additional 14,838 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Entrada Therapeutics by 27.5% in the second quarter. Marshall Wace LLP now owns 65,943 shares of the company's stock worth $940,000 after acquiring an additional 14,220 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Entrada Therapeutics by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company's stock valued at $814,000 after purchasing an additional 2,146 shares in the last quarter. 86.39% of the stock is owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.